Diabetes Type 2 Support Group
Type 2 Diabetes is a condition in which the body either does not produce enough insulin or does not make efficient use of it. Insulin is a hormone needed to convert food into glucose, a sugar that the body uses for energy. Without enough insulin, glucose can accumulate in the blood, and can cause serious health problems such as heart disease and strokes and organ damage...
This is 4 years old article I have not heard of this drug being used for weight loss
The Lancet, Volume 368, Issue 9548, Pages 1660 - 1672, 11 November 2006
doi:10.1016/S0140-6736(06)69571-8Cite or Link Using DOI
Published Online: 27 October 2006
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study
Prof Andr J Scheen MD a , Prof Nick Finer MD b, Prof Priscilla Hollander MD c, Prof Michael D Jensen MD d, Prof Luc F Van Gaal MD e, for the RIO-Diabetes Study Group
Summary
Background
Rimonabant, a selective cannabinoid type 1 receptor blocker, reduces bodyweight and improves cardiovascular and metabolic risk factors in non-diabetic overweight or obese patients. The aim of the RIO-Diabetes trial was to assess the efficacy and safety of rimonabant in overweight or obese patients with type 2 diabetes that was inadequately controlled by metformin or sulphonylureas.
Methods
1047 overweight or obese type 2 diabetes patients (body-mass index 2740 kg/m2) with a haemoglobin A1c (HbA1c) concentration of 65100% (mean 73% [SD 09] at baseline) already on metformin or sulphonylurea monotherapy were given a mild hypocaloric diet and advice for increased physical activity, and randomly assigned placebo (n=348), 5 mg/day rimonabant (360) or 20 mg/day rimonabant (339) for 1 year. Two individuals in the 5 mg/day group did not receive double-blind treatment and were thus not included in the final analysis. The primary endpoint was weight change from baseline after 1 year of treatment. Analyses were done on an intention-to-treat basis. This trial is registered at ClinicalTrials.gov, number NCT00029848.
Findings
692 patients completed the 1 year follow-up; numbers in each group after 1 year were much the same. Weight loss was significantly greater after 1 year in both rimonabant groups than in the placebo group (placebo: 14 kg [SD 36]; 5 mg/day: 23 kg [42], p=001 vs placebo; 20 mg/day: 53 kg [52], p
The Lancet, Volume 368, Issue 9548, Pages 1660 - 1672, 11 November 2006
doi:10.1016/S0140-6736(06)69571-8Cite or Link Using DOI
Published Online: 27 October 2006
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study
Prof Andr J Scheen MD a , Prof Nick Finer MD b, Prof Priscilla Hollander MD c, Prof Michael D Jensen MD d, Prof Luc F Van Gaal MD e, for the RIO-Diabetes Study Group
Summary
Background
Rimonabant, a selective cannabinoid type 1 receptor blocker, reduces bodyweight and improves cardiovascular and metabolic risk factors in non-diabetic overweight or obese patients. The aim of the RIO-Diabetes trial was to assess the efficacy and safety of rimonabant in overweight or obese patients with type 2 diabetes that was inadequately controlled by metformin or sulphonylureas.
Methods
1047 overweight or obese type 2 diabetes patients (body-mass index 2740 kg/m2) with a haemoglobin A1c (HbA1c) concentration of 65100% (mean 73% [SD 09] at baseline) already on metformin or sulphonylurea monotherapy were given a mild hypocaloric diet and advice for increased physical activity, and randomly assigned placebo (n=348), 5 mg/day rimonabant (360) or 20 mg/day rimonabant (339) for 1 year. Two individuals in the 5 mg/day group did not receive double-blind treatment and were thus not included in the final analysis. The primary endpoint was weight change from baseline after 1 year of treatment. Analyses were done on an intention-to-treat basis. This trial is registered at ClinicalTrials.gov, number NCT00029848.
Findings
692 patients completed the 1 year follow-up; numbers in each group after 1 year were much the same. Weight loss was significantly greater after 1 year in both rimonabant groups than in the placebo group (placebo: 14 kg [SD 36]; 5 mg/day: 23 kg [42], p=001 vs placebo; 20 mg/day: 53 kg [52], p
Findings
692 patients completed the 1 year follow-up; numbers in each group after 1 year were much the same. Weight loss was significantly greater after 1 year in both rimonabant groups than in the placebo group (placebo: 14 kg [SD 36]; 5 mg/day: 23 kg [42], p=001 vs placebo; 20 mg/day: 53 kg [52], p
These data indicate that 20 mg/day rimonabant, in combination with diet and exercise, can produce a clinically meaningful reduction in bodyweight and improve HbA1c and a number of cardiovascular and metabolic risk factors in overweight or obese patients with type 2 diabetes inadequately controlled by metformin or sulphonylureas.